imiquimod has been researched along with Erythema in 22 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.55) | 18.2507 |
2000's | 14 (63.64) | 29.6817 |
2010's | 5 (22.73) | 24.3611 |
2020's | 2 (9.09) | 2.80 |
Authors | Studies |
---|---|
Bhuvarahamurthy, S; Kalaiyazhagan, A; Meganathan, J; Ramamoorthy, R; Venugopal, B; Vijayapoopathi, S | 1 |
Funasaka, Y; Kawana, S; Oyama, S; Saeki, H; Tsuchiya, SI | 1 |
Di, TT; Li, P; Lin, Y; Meng, YJ; Wang, MX; Wang, N; Wang, Y; Xie, XJ; Xu, XL; Zhang, L; Zhao, JX | 1 |
Landucci, G; Savoia, P; Tarantino, V; Veronese, F; Zavattaro, E | 1 |
Wang, L; Zeng, Y; Zheng, YQ | 1 |
Schmutz, JL | 1 |
Adams, S; Angiulli, A; Angiulli, F; Berman, RS; Berner, N; Bhardwaj, N; Chiriboga, L; Cruz, CM; Gnjatic, S; Hardin, E; Hoffman, EW; Holman, RM; Jungbluth, A; Manches, O; Nonaka, D; O'Neill, DW; Old, L; Pan, L; Pavlick, AC; Ritter, E; Shao, Y; Shapiro, RL; Siu, K; Venhaus, RR | 1 |
Cannon, PS; Huilgol, SC; O'Donnell, B; Selva, D | 1 |
Bayerl, C; Feller, G; Goerdt, S | 1 |
Cornelison, RL; Crowson, N; Garcia, C; Haque, R; Jankey, C; Kuwahara, R; Mackinnis, C; Naylor, MF; Odom, C; Teague, K | 1 |
Micali, G; Nasca, MR; Tedeschi, A | 1 |
Barnetson, RS; Halliday, GM; Lee, JH; McKane, S; Ooi, T; Slade, HB; Zhuang, L | 1 |
Tanghetti, E; Werschler, P | 1 |
Blasco Melguizo, J; Bukhardt Pérez, MP; Naranjo Díaz, MJ; Naranjo Sintes, R; Ruiz-Villaverde, R | 1 |
Colaco, SM; Heaphy, MR; Palmer, G; Ricotti, CA; Shamma, HN; Trevino, J | 1 |
Bernardino, CR; Murchison, AP; Soloman, AR; Washington, CV | 1 |
Fargnoli, MC; Micantonio, T; Peris, K; Piccolo, D | 1 |
Baker, D; Edwards, L; Eron, L; Ferenczy, A; Fox, TL; Hougham, AJ; Owens, ML; Schmitt, KA | 1 |
Barasso, R; Carey-Yard, M; Eul, A; Gollnick, H; Jappe, U; Milde, K; Ward, K | 1 |
Brown, DR; Douglas, JM; Ferenczy, A; Fife, KH; Owens, ML; Smith, M | 1 |
Barba, AR; Berman, B; Kapoor, S | 1 |
Flowers, F | 1 |
9 trial(s) available for imiquimod and Erythema
Article | Year |
---|---|
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Topics: Adjuvants, Immunologic; Adult; Aged; Aminoquinolines; Antibody Formation; Antigens, Neoplasm; Biopsy; Cancer Vaccines; Epitope Mapping; Erythema; Female; Humans; Imiquimod; Immunization; Male; Melanoma; Membrane Proteins; Middle Aged; Pilot Projects; Toll-Like Receptor 7 | 2008 |
Treatment of lentigo maligna with topical imiquimod.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Cytokines; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Ointments; Skin Ulcer; Treatment Outcome | 2003 |
Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
Topics: Aged; Aminoquinolines; Biomarkers; Cell Movement; Dendritic Cells; Double-Blind Method; Drug Eruptions; Erythema; Female; Humans; Imiquimod; Immunophenotyping; Interferon Inducers; Keratosis; Male; Middle Aged; Photosensitivity Disorders; Skin; T-Lymphocyte Subsets; Treatment Outcome | 2006 |
Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp.
Topics: Administration, Topical; Adult; Aminoquinolines; Disease Management; Erythema; Facial Dermatoses; Fluorouracil; Humans; Imiquimod; Keratosis; Scalp Dermatoses; Treatment Outcome | 2007 |
Laser-assisted tattoo removal with topical 5% imiquimod cream.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Combined Modality Therapy; Double-Blind Method; Erythema; Humans; Imiquimod; Laser Therapy; Prospective Studies; Pruritus; Tattooing | 2007 |
Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Adult; Aminoquinolines; Anus Diseases; Condylomata Acuminata; Dermatitis; Double-Blind Method; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Genital Diseases, Female; Genital Diseases, Male; Humans; Imiquimod; Incidence; Interferon Inducers; Male; Ointments; Pharmaceutical Vehicles; Placebos; Recurrence; Remission Induction; Safety; Self Administration; Treatment Outcome | 1998 |
Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.
Topics: Administration, Topical; Adolescent; Adult; Aminoquinolines; Condylomata Acuminata; Erythema; France; Germany; Humans; Imiquimod; Interferon Inducers; Male; Pain; Penile Diseases; Pruritus | 2001 |
Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
Topics: Adult; Aged; Aminoquinolines; Antibodies, Viral; Condylomata Acuminata; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Humans; Imiquimod; Interferon Inducers; Male; Middle Aged; Neopterin; Papillomaviridae; Ulcer | 2001 |
An open label safety study of topical imiquimod 5% cream in the treatment of Molluscum contagiosum in children.
Topics: Administration, Topical; Adolescent; Aminoquinolines; Child; Child, Preschool; Erythema; Humans; Imiquimod; Infant; Interferon Inducers; Molluscum Contagiosum; Pruritus | 2001 |
13 other study(ies) available for imiquimod and Erythema
Article | Year |
---|---|
Nutraceutical combination ameliorates imiquimod-induced psoriasis in mice.
Topics: Animals; Cannabidiol; Dietary Supplements; Disease Models, Animal; Erythema; Humans; Imiquimod; Inositol; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Cell Count; Dermis; Dermoscopy; Erythema; Female; Humans; Imiquimod; Immunohistochemistry; Keratosis, Actinic; Ki-67 Antigen; Male; Mast Cells; Proto-Oncogene Proteins c-kit; Toll-Like Receptor 7; Treatment Outcome | 2017 |
Acetyl-11-keto-β-boswellic acid inhibits the secretion of cytokines by dendritic cells via the TLR7/8 pathway in an imiquimod-induced psoriasis mouse model and in vitro.
Topics: Aminoquinolines; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Coculture Techniques; Cytokines; Dendritic Cells; Erythema; Imiquimod; Inflammation; Interleukin-12 Subunit p35; Interleukin-23 Subunit p19; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Psoriasis; RNA, Messenger; Signal Transduction; Spleen; Toll-Like Receptor 7; Toll-Like Receptor 8; Triterpenes | 2018 |
Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Erythema; Female; Humans; Imiquimod; Immunocompromised Host; Keratosis, Actinic; Male; Middle Aged; Scalp; Treatment Outcome | 2020 |
Vagarious successful treatment of recalcitrant warts in combination with CO2 laser and imiquimod 5% cream.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Child; Combined Modality Therapy; Erythema; Female; Humans; Imiquimod; Lasers, Gas; Warts | 2014 |
[Adverse effects of Aldara(®): polymorphous erythema and chronic ulceration].
Topics: Aminoquinolines; Antineoplastic Agents; Erythema; Humans; Imiquimod; Skin Ulcer | 2015 |
The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Conjunctivitis; Erythema; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2011 |
Experience in treating molluscum contagiosum in children with imiquimod 5% cream.
Topics: Adjuvants, Immunologic; Aminoquinolines; Child; Child, Preschool; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Humans; Imiquimod; Male; Molluscum Contagiosum; Ointments; Pain; Pruritus | 2003 |
Topical treatment of intraepithelial penile carcinoma with imiquimod.
Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Erythema; Humans; Imiquimod; Male; Middle Aged; Pain; Penile Neoplasms; Treatment Outcome | 2003 |
Basal cell carcinoma: treatment with imiquimod.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Aminoquinolines; Biopsy; Carcinoma, Basal Cell; Erythema; Female; Humans; Imiquimod; Male; Middle Aged; Skin; Skin Neoplasms; Spain; Time Factors; Treatment Outcome | 2007 |
Ocular effects of imiquimod with treatment of eyelid melanoma in situ.
Topics: Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Conjunctiva; Erythema; Eyelid Neoplasms; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Skin; Skin Neoplasms; Visual Acuity | 2007 |
Letter: Changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Dermoscopy; Drug Monitoring; Erythema; Female; Humans; Imiquimod; Immunologic Factors; Male; Middle Aged; Remission Induction; Skin Neoplasms; Skin Ulcer | 2007 |
Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasms.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Bowen's Disease; Cicatrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis; Paget Disease, Extramammary; Photochemotherapy; Pruritus; Randomized Controlled Trials as Topic; Skin Neoplasms | 2002 |